D.E. Shaw & Co
ZYNE

D.E. Shaw & Co’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

D.E. Shaw & Co’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-195,064
Closed -$103K – 5052
2022
Q4 		$103K Sell
195,064
-372,052
-66% -$236K ﹤0.01% 4359
2022
Q3 		$415K Sell
567,116
-542,039
-49% -$615K ﹤0.01% 4144
2022
Q2 		$1.26M Sell
1,109,155
-99,725
-8% -$127K ﹤0.01% 3468
2022
Q1 		$2.48M Buy
1,208,880
+51,468
+4% +$122K ﹤0.01% 3106
2021
Q4 		$3.33M Sell
1,157,412
-248,577
-18% -$920K ﹤0.01% 2832
2021
Q3 		$5.96M Buy
1,405,989
+332,989
+31% +$1.49M 0.01% 1942
2021
Q2 		$5.68M Buy
1,073,000
+765,962
+249% +$3.68M ﹤0.01% 1933
2021
Q1 		$1.43M Buy
307,038
+268,880
+705% +$1.22M ﹤0.01% 2843
2020
Q4 		$126K Buy
+38,158
New +$145K ﹤0.01% 3795
2017
Q4 		– Sell
-29,997
Closed -$251K – 3790
2017
Q3 		$251K Buy
+29,997
New +$317K ﹤0.01% 3209

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's ZYNE Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 195,064 shares — an estimated $103K sold.

D.E. Shaw & Co first reported a position in ZYNE in Q3 2017 and held it in 10 quarters. The position peaked at $5.96M in Q3 2021. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • D.E. Shaw & Co reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 195,064 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $103K.
  • D.E. Shaw & Co first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and held it in 10 quarters.
  • D.E. Shaw & Co's Zynerba Pharmaceuticals, Inc position peaked at $5.96M in Q3 2021.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.